Webinar: Advancing T cell Therapies Using B-hCD3 Mouse Models
We are pleased to launch a new webinar series!
Our webinar “Advancing T cell Therapies Using B-hCD3 Mouse Models” was live on Oct 28 at 1PM.
In this webinar, we will review and discuss in-depth:
● Current challenges in screening leads and evaluating antibody candidates developed for T cell-mediated immunotherapy
● Generation and validation data for our humanized B-hCD3E and B-hCD3EDG mice
● The preservation of normal immune cell profiles and T cell activation in these models
● The In vivo efficacy of anti-CD3 therapeutics using MC38 tumor models in our CD3-humanized mice
About the Speaker & Panelists
John Charpentier, Ph.D.
Business Development Manager, Biocytogen Boston
A native of New England, John has spent nearly a decade in laboratories focused on questions of fundamental T cell biology. After earning a Ph.D. in immunology from the University of Michigan, he returned home to Boston in July 2021 to join Biocytogen as a Business Development Manager. In this role he liaises between Biocytogen’s clients and scientific teams to ensure collaboration success.
Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston
Dr. Jenna Frame has worked with mouse and zebrafish models in the hematology field for over 15 years at the University of Rochester and Harvard Medical School. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their research pipeline.
Q & A:
Qingcong Lin, Ph.D. Senior Vice President and CEO of Biocytogen Boston
Dr. Lin has extensive research expertise in the field of molecular genetics. He has held leadership positions at Wyeth and Pfizer, and has served as the Director of the Laboratory for Genetic Engineering at the Center for Genetics and Genomics Research at Harvard Medical School. In 2018, Dr. Lin joined Biocytogen as the Senior Vice President and President of Biocytogen Boston. He is fully responsible for the company’s US and EU business development, including licensing the use of RenMab mice, the external authorization and cooperative development of therapeutic antibody candidates, including pharmacology and efficacy studies, and development of gene targeting business.